Elegen

Innovation Is Our DNA

Employees
11–50
Total Funding
$35.0M
Last Round
$35.0M Series BMay 2024
Rounds
1

About

Elegen is a synthetic biology company that has developed ENFINIA™, the world's only entirely cell-free platform for rapid, high-quality DNA production. Using patented microfluidic synthesis, AI, and robotics, Elegen delivers long, clonal-quality, high-complexity DNA — including linear, plasmid, and IVT-ready formats — in 6 to 8 business days with 99.999% per-base accuracy. Unlike traditional approaches that require bacterial cloning and colony screening, Elegen's cell-free process eliminates bioburden, recombination, and foundry dependencies. ENFINIA DNA serves applications in cell and gene therapy, mRNA vaccines, personalized cancer vaccines, and protein expression, enabling faster and more reliable development of next-generation biologics.

Summary

Elegen is a Healthcare company. It has raised $35.0M in total across 1 round, most recently a $35.0M Series B round in May 2024. Investors include Triatomic Capital and Andreessen Horowitz.

Tech & App Stack

4 technologies & apps tracked

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Series BSeries BMay 2024
$35.0M

Investors

Similar Companies